IL307593A - Pharmaceutical preparation for use in the treatment and prevention of C5-related diseases and methods for the treatment and prevention of C5-related diseases - Google Patents
Pharmaceutical preparation for use in the treatment and prevention of C5-related diseases and methods for the treatment and prevention of C5-related diseasesInfo
- Publication number
- IL307593A IL307593A IL307593A IL30759323A IL307593A IL 307593 A IL307593 A IL 307593A IL 307593 A IL307593 A IL 307593A IL 30759323 A IL30759323 A IL 30759323A IL 307593 A IL307593 A IL 307593A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- days
- dose
- composition
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 114
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 55
- 201000010099 disease Diseases 0.000 title description 53
- 238000000034 method Methods 0.000 title description 47
- 230000002265 prevention Effects 0.000 title description 17
- 239000000203 mixture Substances 0.000 description 117
- 238000010254 subcutaneous injection Methods 0.000 description 102
- 239000007929 subcutaneous injection Substances 0.000 description 97
- 238000010253 intravenous injection Methods 0.000 description 75
- 230000002378 acidificating effect Effects 0.000 description 36
- 230000007935 neutral effect Effects 0.000 description 34
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 34
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 33
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 33
- 230000000144 pharmacologic effect Effects 0.000 description 32
- 229960002224 eculizumab Drugs 0.000 description 29
- 102100031506 Complement C5 Human genes 0.000 description 26
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 26
- 239000000427 antigen Substances 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 20
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 19
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 18
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 15
- 230000003285 pharmacodynamic effect Effects 0.000 description 15
- 230000036470 plasma concentration Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 206010018910 Haemolysis Diseases 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000024203 complement activation Effects 0.000 description 14
- 230000008588 hemolysis Effects 0.000 description 14
- 238000001802 infusion Methods 0.000 description 14
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 12
- 208000022401 dense deposit disease Diseases 0.000 description 12
- 231100000562 fetal loss Toxicity 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 201000006417 multiple sclerosis Diseases 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 11
- 241000282567 Macaca fascicularis Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 6
- 208000005777 Lupus Nephritis Diseases 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 6
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000002612 cardiopulmonary effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001631 haemodialysis Methods 0.000 description 6
- 230000000322 hemodialysis Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000009529 traumatic brain injury Effects 0.000 description 6
- 101100069975 Caenorhabditis elegans his-72 gene Proteins 0.000 description 5
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 5
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001163 endosome Anatomy 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101100177112 Caenorhabditis elegans his-70 gene Proteins 0.000 description 4
- 108010073807 IgG Receptors Proteins 0.000 description 4
- 102000009490 IgG Receptors Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010089414 Anaphylatoxins Proteins 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- -1 Val71 Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 108700040669 phosphatidylinositol glycan-class A Proteins 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102100027715 4-hydroxy-2-oxoglutarate aldolase, mitochondrial Human genes 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 108010028773 Complement C5 Proteins 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 2
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001081225 Homo sapiens 4-hydroxy-2-oxoglutarate aldolase, mitochondrial Proteins 0.000 description 2
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 2
- 101000604027 Homo sapiens Nuclear protein localization protein 4 homolog Proteins 0.000 description 2
- 101000974007 Homo sapiens Nucleosome assembly protein 1-like 3 Proteins 0.000 description 2
- 101001099181 Homo sapiens TATA-binding protein-associated factor 2N Proteins 0.000 description 2
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 2
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 2
- 102100038438 Nuclear protein localization protein 4 homolog Human genes 0.000 description 2
- 102100038917 TATA-binding protein-associated factor 2N Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000004074 complement inhibitor Substances 0.000 description 2
- 108010032939 des-Arginine Complement C5a Proteins 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 108090000062 ficolin Proteins 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 201000001505 hemoglobinuria Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102100024508 Ficolin-1 Human genes 0.000 description 1
- 102100024521 Ficolin-2 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018901 Haemoglobinaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010085169 Lysine carboxypeptidase Proteins 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150092843 SEC1 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201700775YA SG10201700775YA (en) | 2017-01-31 | 2017-01-31 | A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease |
| SG10201705954VA SG10201705954VA (en) | 2017-07-20 | 2017-07-20 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| PCT/JP2018/003193 WO2018143266A1 (en) | 2017-01-31 | 2018-01-31 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307593A true IL307593A (en) | 2023-12-01 |
Family
ID=61617058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307593A IL307593A (en) | 2017-01-31 | 2018-01-31 | Pharmaceutical preparation for use in the treatment and prevention of C5-related diseases and methods for the treatment and prevention of C5-related diseases |
| IL268327A IL268327A (en) | 2017-01-31 | 2019-07-29 | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268327A IL268327A (en) | 2017-01-31 | 2019-07-29 | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20190367599A1 (ko) |
| EP (2) | EP3577135B1 (ko) |
| JP (3) | JP6383122B2 (ko) |
| KR (4) | KR102514175B1 (ko) |
| CN (1) | CN110167961A (ko) |
| AU (1) | AU2018215039B2 (ko) |
| BR (1) | BR112019015426A2 (ko) |
| CA (1) | CA3051389A1 (ko) |
| CR (2) | CR20190403A (ko) |
| ES (1) | ES2947735T3 (ko) |
| IL (2) | IL307593A (ko) |
| MX (2) | MX2019007749A (ko) |
| MY (1) | MY201148A (ko) |
| PH (1) | PH12019501706A1 (ko) |
| PL (1) | PL3577135T3 (ko) |
| SG (2) | SG10201908697XA (ko) |
| TW (3) | TWI828672B (ko) |
| WO (1) | WO2018143266A1 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| KR20230044338A (ko) | 2014-12-19 | 2023-04-03 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
| CN116751293A (zh) | 2016-06-14 | 2023-09-15 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| US20200254092A1 (en) * | 2017-10-26 | 2020-08-13 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| EP4003408A1 (en) * | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| CN114929273A (zh) * | 2019-07-31 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
| CN115052889A (zh) * | 2019-10-25 | 2022-09-13 | 瑞泽恩制药公司 | 用于治疗或预防c5相关疾病的给药方案 |
| CA3196434A1 (en) * | 2020-10-23 | 2022-04-28 | Krista K. JOHNSON | Methods of treating patients having complement disorders using anti-c5 antibodies |
| JP2024060738A (ja) | 2022-10-20 | 2024-05-07 | セイコーエプソン株式会社 | 気体分離膜 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1325033B1 (en) | 2000-10-10 | 2009-11-25 | Genentech, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| ATE360441T1 (de) | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
| AR072897A1 (es) | 2008-08-05 | 2010-09-29 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 |
| CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| PL2970974T3 (pl) * | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
| WO2014160958A1 (en) * | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| KR20230044338A (ko) * | 2014-12-19 | 2023-04-03 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
| WO2016209956A1 (en) * | 2015-06-26 | 2016-12-29 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| WO2017123636A1 (en) | 2016-01-11 | 2017-07-20 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| US20190085095A1 (en) | 2016-01-25 | 2019-03-21 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
-
2018
- 2018-01-31 SG SG10201908697X patent/SG10201908697XA/en unknown
- 2018-01-31 TW TW108110617A patent/TWI828672B/zh active
- 2018-01-31 MY MYPI2019004320A patent/MY201148A/en unknown
- 2018-01-31 EP EP18710159.7A patent/EP3577135B1/en active Active
- 2018-01-31 KR KR1020227005327A patent/KR102514175B1/ko active IP Right Grant
- 2018-01-31 KR KR1020197004219A patent/KR102365871B1/ko active IP Right Grant
- 2018-01-31 KR KR1020187009861A patent/KR101949891B1/ko active IP Right Grant
- 2018-01-31 EP EP23165354.4A patent/EP4223774A3/en active Pending
- 2018-01-31 JP JP2018014743A patent/JP6383122B2/ja active Active
- 2018-01-31 IL IL307593A patent/IL307593A/en unknown
- 2018-01-31 MX MX2019007749A patent/MX2019007749A/es unknown
- 2018-01-31 KR KR1020237009640A patent/KR20230043247A/ko not_active Application Discontinuation
- 2018-01-31 TW TW107103450A patent/TWI658834B/zh active
- 2018-01-31 SG SG11201801401UA patent/SG11201801401UA/en unknown
- 2018-01-31 CR CR20190403A patent/CR20190403A/es unknown
- 2018-01-31 BR BR112019015426-4A patent/BR112019015426A2/pt unknown
- 2018-01-31 PL PL18710159.7T patent/PL3577135T3/pl unknown
- 2018-01-31 WO PCT/JP2018/003193 patent/WO2018143266A1/en active Application Filing
- 2018-01-31 TW TW112148241A patent/TW202412841A/zh unknown
- 2018-01-31 AU AU2018215039A patent/AU2018215039B2/en active Active
- 2018-01-31 CA CA3051389A patent/CA3051389A1/en active Pending
- 2018-01-31 US US16/480,047 patent/US20190367599A1/en not_active Abandoned
- 2018-01-31 ES ES18710159T patent/ES2947735T3/es active Active
- 2018-01-31 CN CN201880005975.XA patent/CN110167961A/zh active Pending
- 2018-01-31 CR CR20220563A patent/CR20220563A/es unknown
- 2018-06-22 JP JP2018118937A patent/JP7141865B2/ja active Active
-
2019
- 2019-06-26 MX MX2022012931A patent/MX2022012931A/es unknown
- 2019-07-24 PH PH12019501706A patent/PH12019501706A1/en unknown
- 2019-07-29 IL IL268327A patent/IL268327A/en unknown
-
2020
- 2020-07-14 US US16/928,129 patent/US20200407432A1/en not_active Abandoned
-
2022
- 2022-09-12 JP JP2022144425A patent/JP2022168209A/ja active Pending
-
2023
- 2023-03-10 US US18/181,641 patent/US20230250162A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200407432A1 (en) | Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| AU2019315213B2 (en) | A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease | |
| RU2786053C2 (ru) | Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания | |
| RU2789389C2 (ru) | Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с с5 заболевания, и способ лечения или предупреждения связанного с с5 заболевания | |
| KR20240115904A (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |